Copyright
©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1361-1372
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Table 4 SVR12 in hepatitis C virus genotype 1b-infected patients with and without resistance-associated polymorphisms at baseline (placebo-deferred treatment arm) n (%)
| All patients - placebo-deferred treatment arm | |||||||||
| With RAPs at baseline | Without RAPs at baseline | ||||||||
| Mainland China | Russia | South Korea | Overall | Mainland China | Russia | South Korea | Overall | ||
| NS5A-L31M/V | 0 | 0 | 0 | 0 | 33/41 (80.5) | 6/6 (100) | 3/3 (100) | 42/50 (84.0) | |
| Y93H | 2/8 (25.0) | 0 | 0 | 2/8 (25.0) | 31/33 (93.9) | 6/6 (100) | 3/3 (100) | 40/42 (95.2) | |
| L31M/V or Y93H | 2/8 (25.0) | 0 | 0 | 2/8 (25.0) | 31/33 (93.9) | 6/6 (100) | 3/3 (100) | 40/42 (95.2) | |
| NS3-D168E | 0 | 0 | 0 | 0 | 33/41 (80.5) | 6/6 (100) | 3/3 (100) | 42/50 (84.0) | |
- Citation: Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372
- URL: https://www.wjgnet.com/1007-9327/full/v24/i12/1361.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i12.1361